摘要
目的:探讨难治性心力衰竭患者采用防己黄芪汤合真武汤辅助治疗的临床效果。方法:选择2022年1月—2023年12月滕州市中医医院收治的86例难治性心力衰竭患者,采用随机数字表法分为试验组(n=43)、对照组(n=43)。对照组患者接受基础对症治疗,试验组患者增加防己黄芪汤合真武汤加减治疗。比较两组中医症候积分、心功能、脑钠肽(BNP)、谷胱甘肽过氧化物酶(GSH-Px)、半乳糖凝集素-3(Gal-3)。结果:治疗后试验组中医症候积分均低于对照组,差异均有统计学意义(P<0.05);治疗后试验组左室射血分数(LVEF)高于对照组,左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)均小于对照组,差异均有统计学意义(P<0.05);治疗后试验组BNP、Gal-3水平均低于对照组,GSH-Px水平高于对照组,差异均有统计学意义(P<0.05)。结论:难治性心力衰竭患者基础对症治疗效果不理想,患者病情仍然进展,采用防己黄芪汤合真武汤加减辅助治疗可控制疾病进展。
Objective:To explore the clinical effect of modified Fangji Huangqi Decoction combined with Zhenwu Decoction in the adjuvant treatment of patients with refractory heart failure.Method:A total of 86 patients with refractory heart failure treated in Tengzhou Traditional Chinese Medical Hospital from January 2022 to December 2023 were selected and divided into experimental group(n=43)and control group(n=43)by random number table method.Patients in the control group received basic symptomatic treatment,patients in the experimental group added modified Fangji Huangqi Decoction combined with Zhenwu Decoction treatment.The TCM syndromes scores,cardiac function,brain natriuretic peptide(BNP),glutathione peroxidase(GSH-Px)and galactin-3(Gal-3)were compared between the two groups.Result:After treatment,TCM syndromes scores in experimental group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,left ventricular ejection fraction(LVEF)of experimental group was higher than that of control group,and left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD)of experimental group were smaller than those of control group,the differences were statistically significant(P<0.05).After treatment,the levels of BNP and Gal-3 in experimental groups were lower than those in control group,and the level of GSH-Px was higher than that in control group,the differences were statistically significant(P<0.05).Conclusion:The effect of basic symptomatic treatment for patients with refractory heart failure is not ideal,the patient's condition is still progressive,using modified Fangji Huangqi Decoction combined with Zhenwu Decoction adjuvant treatment can control the disease progression.
作者
黄文
盖志青
宋现丽
HUANG Wen;GE Zhiqing;SONG Xianli(不详;Department of Cardiovascular Medicine,Tengzhou Traditional Chinese Medical Hospital,Tengzhou 277599,China)
出处
《中国医学创新》
CAS
2024年第21期98-101,共4页
Medical Innovation of China
关键词
难治性心力衰竭
防己黄芪汤合真武汤
螺内酯
Refractory heart failure
Fangji Huangqi Decoction combined with Zhenwu Decoction
Spirolactone